Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Waldencast plc - Class A Ordinary Share (NQ:WALD)

1.610 -0.020 (-1.23%)
Streaming Delayed Price Updated: 3:09 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Waldencast plc - Class A Ordinary Share

< Previous 1 2 3 4 5 6 7 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates
First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 
From Waldencast plc
Via GlobeNewswire
News headline image
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* 
From Waldencast plc
Via GlobeNewswire
News headline image
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market 
From Waldencast plc
Via GlobeNewswire
News headline image
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
From Waldencast plc
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Earnings Scheduled For August 18, 2025 ↗
 
Via Benzinga
News headline image
Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
 
Via Benzinga
News headline image
Gore Range Capital Announces Sale of Novaestiq Corp. to Waldencast
Via ACCESS Newswire
News headline image
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
From Waldencast plc
Via GlobeNewswire
News headline image
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Waldencast Reports Q1 2025 Financial Results
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Q1 Preview: Beauty Brand Glow Dims On Soft Margins, Flat Sales ↗
WALD is reporting Q1 results on May 13, Telsey Advisory Group expects margin and earnings miss. Analyst Dana Telsey maintains outperform rating. 
Via Benzinga
Topics Earnings
News headline image
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Reports Q4 2024 and Fiscal Year 2024 Financial Results
From Waldencast plc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 18, 2025 ↗
 
Via Benzinga
News headline image
Waldencast plc Announces Fourth Quarter and Fiscal Year 2024 Results Conference Call and Webcast
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Q4 Earnings Preview: All Eyes On Tariff Impact, Obagi Skincare Brand ↗
Waldencast is set to report Q4 earnings, with analysts projecting $81.69M sales. The company expands Obagi globally while mitigating potential tariff impacts. 
Via Benzinga
Topics World Trade
News headline image
Waldencast Announces Participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
From Waldencast plc.
Via GlobeNewswire
News headline image
Obagi Medical Announces the Launch of Latest Innovations in The SUZANOBAGIMD® Collection
New Skincare Solutions to Target Skin Brightening, Oxidative Stress, and Hydration for a Healthier, More Radiant Complexion 
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast plc Announces Upcoming Earnings Release and Conference Call Dates
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Announces Participation in the 2025 IMCAS World Congress
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Announces Participation in the ICR Conference 2025
From Waldencast plc.
Via GlobeNewswire
News headline image
Waldencast Reports Q3 2024 Financial Results
From Waldencast plc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.